On August 26th, 2014 Frank Curzio, published an article on Stockhouse entitled "Investing In The Future Of Cancer Treatment". Curzio opened the article with the implication that the development of Immune System Activating Drugs could become "The Third Step In The War Against Cancer". In conformity with his above titled journalistic and analyst peers, Curzio only mentions the names of big blue chip companies that are in the race to develop immune system activating drugs, see quote below... However, he does clearly urge readers to look past the majors and find small capitalization companies, that he believes will provide life changing returns. His ominous prophecy is that the smaller companies will possibly produce life elevating financial results in the lives of those who invest early. Please visit the link to Stockhouse to read all of the article.
Stockhouse has previously published several articles on Cellceutix (OTCMKTS:CTIX). One of them was on Cellceutix' Autism drug, Autism is a subject that Apple CEO (NASDAQ:APPL), Tim Cook passionately mentioned during the last Apple annual meeting. Perhaps Mr. Cook, needs to meet with Dr. Krishna Menon, almost as much as the late Steve Jobs needed too.
"Some of the big winners of the immunotherapy trend will be pharmaceutical giants that have made major investments in the immunotherapy space, like Merck (OTO: MKGAY, Stock Forum), Roche Holdings AG (OTO: RHHVF, Stock Forum), and Bristol-Myers Squibb Co. (NYSE: BMY, Stock Forum).
However, the biggest beneficiaries will be smaller names developing early-stage immunotherapy technologies to help treat cancer patients all over the world. My advice is start researching small immunotherapy names with experienced management teams, solid balance sheets, and partnerships with large pharmaceutical companies like the ones I mentioned above... Curzio continues
The long-awaited revolution in the fight against cancer is here. And this trend could offer life-changing returns for early investors over the next few years. The key is investing now... before immunotherapy hits the mainstream."
Read more at www.stockhouse.com/opinion/independent-r...
I believe that Mr Curzio, has probably read quite a bit about Cellceutix, and I would surmise that he is possibly a shareholder. Who will be the first journalist or analyst that will take the huge gothic risk of doing what Harvard's Dana Farber, MD Anderson, Harvard's Beth Israel and The University of Bologna have all done? To go where no other major journalist or analyst has ever gone before, publicly identify that Cellceutix', Kevetrin is perhaps the leading compound in the cancer immune therapy race.
I simply invite the wonderful informed people on I HUB and elsewhere to enter comments in the comment section below, with regards to Kevetrin and also Brilacidin. I HUB Cellceutix, is a treasure chest, its moderators have done a stellar job.
Frank could have mentioned that Dana Farber is the worlds historic center for chemotherapy and its advances. Dana Farber, is also in conversation with MD Anderson, known as the leading Cancer research development institution in the world. Little wonder that Kevetrin is at Dana Farber and MD Anderson. Cellceutix was the smallest capitalization public company that has had a compound accepted into FDA trials at Dana Farber.
According to government regulations as I understand them, small capitalization companies must be treated as riskier than Lottery Tickets. So please consider that any shares purchased in a small cap stock, can turn to hock!